Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
1(20%)
Results Posted
200%(4 trials)
Terminated
2(40%)

Phase Distribution

Ph phase_2
1
20%
Ph phase_1
4
80%

Phase Distribution

4

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
4(80.0%)
Phase 2Efficacy & side effects
1(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(2)
Terminated(2)

Detailed Status

Completed2
Terminated2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (80.0%)
Phase 21 (20.0%)

Trials by Status

recruiting120%
completed240%
terminated240%

Recent Activity

1 active trials
Showing 5 of 5
recruitingphase_1

Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma

NCT06995872
completedphase_1

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

NCT03388632
completedphase_1

Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies

NCT03905135
terminatedphase_2

Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma

NCT04150562
terminatedphase_1

Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia

NCT03759184

Clinical Trials (5)

Showing 5 of 5 trials
NCT06995872Phase 1

Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma

Recruiting
NCT03388632Phase 1

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

Completed
NCT03905135Phase 1

Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies

Completed
NCT04150562Phase 2

Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma

Terminated
NCT03759184Phase 1

Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5